Palvella Therapeutics (PVLA) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 51.8% versus a loss of 29.2%. Over five years, PVLA leads with a -48.4% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.09 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | RCUS |
|---|---|---|
| Share price | $142.85 | $15.62 |
| Market cap | $2.09B | $2.25B |
| 1-day change | -2.00% | -1.01% |
| YTD return | +36.48% | -34.45% |
| 1-year return | +51.82% | -29.16% |
| 5-year return | -48.39% | -66.31% |
| EPS (TTM) | $-5.53 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $247.00M |
| Revenue growth (YoY) | — | -4.26% |
| Net income (latest FY) | $-41.72M | $-353.00M |
| Operating margin | — | -156.28% |
| Net margin | — | -142.91% |
| 52-week high | $179.95 | $31.74 |
| 52-week low | $72.23 | $15.56 |
| Distance from 52-week high | -20.62% | -50.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.42% | +162.48% |
| Average volume | 240.41K | 1.85M |
| Shares outstanding | 14.62M | 143.99M |
| Employees | 29 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed RCUS by 81.0 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
PVLA vs RCUS FAQ
Which is bigger, Palvella Therapeutics or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.09B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, PVLA or RCUS?
PVLA returned +51.82% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.